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Abstract Postherpetic neuralgia (PHN) represents a
potentially debilitating and often undertreated form of
neuropathic pain that disproportionately affects vulnerable
populations, including the elderly and the immunocom-
promised. Varicella zoster infection is almost universally
prevalent, making prevention of acute herpes zoster (AHZ)
infection and prompt diagnosis and aggressive manage-
ment of PHN of critical importance. Despite the recent
development of a herpes zoster vaccine, prevention of AHZ
is not yet widespread or discussed in PHN treatment
guidelines. Diagnosis of PHN requires consideration of
recognized PHN signs and known risk factors, including
advanced age, severe prodromal pain, severe rash, and
AHZ location on the trigeminal dermatomes or brachial
plexus. PHN pain is typically localized, unilateral and
chronic, but may be constant, intermittent, spontaneous
and/or evoked. PHN is likely to interfere with sleep and
daily activities. First-line therapies for PHN include tricy-
clic antidepressants, gabapentin and pregabalin, and the
lidocaine 5 % patch. Second-line therapies include strong
and weak opioids and topical capsaicin cream or 8 %
patch. Tricyclic antidepressants, gabapentinoids and strong
opioids are effective but are also associated with systemic
adverse events that may limit their use in many patients,
most notably those with significant medical comorbidities
or advanced age. Of the topical therapies, the topical
lidocaine 5 % patch has proven more effective than cap-
saicin cream or 8 % patch and has a more rapid onset of
action than the other first-line therapies or capsaicin. Given
the low systemic drug exposure, adverse events with top-
ical therapies are generally limited to application-site
reactions, which are typically mild and transient with
lidocaine 5 % patch, but may involve treatment-limiting
discomfort with capsaicin cream or 8 % patch. Based on
available clinical data, clinicians should consider admin-
istering the herpes zoster vaccine to all patients aged
60 years and older. Clinicians treating patients with PHN
may consider a trial of lidocaine 5 % patch monotherapy
before resorting to a systemic therapy, or alternatively, may
consider administering the lidocaine 5 % patch in combi-
nation with a tricyclic antidepressant or a gabapentinoid to
provide more rapid analgesic response and lower the dose
requirement of systemic therapies.
1 Introduction
Reactivation of a dormant varicella zoster virus, the virus
that causes chicken pox, yields acute herpes zoster (AHZ)
or shingles, a painful blistering skin rash [1, 2]. More than
95 % of the adult population in developed countries man-
ifest seropositivity for antibodies to the varicella zoster
virus, and are, thus, at risk for developing AHZ [1]. After
the initial varicella zoster infection, the virus persists in the
ganglia of the sensory cranial nerves and spinal dorsal root
ganglia without triggering symptoms for many years [2].
However, with age-, stress- or illness-related diminution in
cell-mediated immunity, the risk for AHZ increases.
Indeed, AHZ affects approximately 33 % of the population
and generally, the risk increases dramatically with age [1–3].
S. Nalamachu (&)
International Clinical Research Institute, Inc., 8675 College
Blvd, Suite 150, Overland Park, KS 66210, USA
e-mail: nalamachu@yahoo.com
P. Morley-Forster
Interdisciplinary Pain Program, University of Western Ontario,
St. Josephs Hospital, Room B3-628, 268 Grosvenor Street,
London, ON N6A 4V2, Canada
e-mail: pat.morley-forster@sjhc.london.on.ca
Drugs Aging (2012) 29:863–869
DOI 10.1007/s40266-012-0014-3
The Olmsted County Study found that the incidence of
AHZ was 3.6 cases per 1,000 person-years, but was low in
individuals aged 20–29 years and spiked to 7.1 cases per
1,000 person-years in the seventh decade of life and
reached 12.0 cases per 1,000 person years in individuals
aged C80 years. In all, 51 % of AHZ infection cases
occurred in individuals aged C60 years, although this age
group represents only 23 % of the US population [4].
Although the symptoms of AHZ typically resolve within
2–4 weeks, approximately 10 % of patients develop pos-
therpetic neuralgia (PHN), often defined as pain persisting
more than 3 months after the onset of the rash in the same
affected area (Fig. 1) [3, 5]. The risk of PHN increases with
age. In the Olmsted County Study, 73 % of PHN cases
were in individuals aged C60 years [4]. PHN pain results
from sensory nerve damage and may be intermittent,
chronic or spontaneous in nature [2]. PHN symptoms fre-
quently include allodynia, wherein pain is evoked by nor-
mally nonpainful mechanical stimuli, such as light
brushing of the skin. Even with appropriate treatment, PHN
pain can interfere with sleep and routine daily activities.
Despite the potentially debilitating nature of this disor-
der, PHN tends to be underdiagnosed and inadequately
managed, especially in primary care. Several factors may
contribute to the undertreatment of PHN. When a patient
reports chronic pain, clinicians may not always follow up
by taking a complete patient history or performing a
thorough physical examination to identify the source of the
pain, steps particularly important in elderly and medically
complicated patients who are at high risk of PHN. Addi-
tionally, clinicians may not be familiar with the symptoms
of PHN and the most effective available treatment options.
This review provides essential information that will enable
clinicians to correctly diagnosis PHN and select the most
appropriate pharmacotherapy for their patients with PHN.
2 Prevention of Acute Herpes Zoster
A herpes zoster vaccine (Zostavax) received US FDA
approval in 2006 for use in adults aged 60 years or older
[6] and in 2011 was approved for use in those aged
C50 years [7]. In the Shingles Prevention Study, a
large ([38,000 subjects), 3-year trial in older adults
(C60 years), subjects were randomized to treatment with
either the herpes zoster vaccine or placebo [8]. The vac-
cine reduced the incidence of herpes zoster infection
versus placebo by approximately 50 % (315 cases vs. 642
cases). A total of 107 subjects experienced PHN. The
herpes zoster vaccine was shown to significantly reduce
the incidence of PHN versus placebo by approximately
two-thirds (27 cases vs. 80 cases; p \ 0.001). Greater
reductions in PHN than in AHZ suggest that vaccinated
patients who develop AHZ are less likely to progress to
PHN.
In the Shingles Prevention Study, other investigators
have shown that the herpes zoster vaccine was well toler-
ated, with the incidence of serious adverse events similar to
that seen with placebo [9]. However, this study excluded
subjects with prior herpes zoster infection younger than
60 years and immunocompromised individuals, and it was
conducted only in the USA. As a consequence, the findings
cannot be generalized to all populations at risk for PHN
[6]. A subsequent study evaluating [22,000 individuals
aged 50–59 years in the USA and Europe found that the
vaccination reduced the incidence of AHZ by approxi-
mately 70 %, although the study period was only 1 year
[10].
In addition, a vaccine cost-effectiveness analysis based
on the Shingles Prevention Study demonstrated that the
benefits of the vaccine were not evenly distributed [11].
Although the vaccine was most effective in younger
Fig. 1 Left image shows typical
presentation of acute herpes
zoster. Right image illustrates
typical presentation of
postherpetic neuralgia, with
pain persisting [4 months after
the acute rash, which may have
completely disappeared or left
scant scarring
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patients, most cases of herpes zoster and PHN emerge in
older patients. The analysis revealed that the vaccine was
most cost-effective for patients aged 70 years. Further, for
all ages older than 60 years, the vaccine was more cost-
effective in women than in men, because women are
disproportionately affected by herpes zoster and PHN
compared with men.
It should be noted that the herpes zoster vaccine is a live
virus vaccine and should not be administered to most
immunocompromised patients, including patients with
acquired or primary immunodeficiency, and must be
administered with caution in patients receiving immuno-
suppressive drugs such as prednisone [12]. Immunocom-
promised patients represent nearly 10 % of patients with
AHZ [4]; hence, a substantial proportion of patients at risk
for AHZ cannot be vaccinated.
Despite these caveats, the Centers for Disease Control
and Prevention Advisory Committee on Immunization
Practices now advocates the regular use of the herpes
zoster vaccine in immunocompetent patients aged
60 years and older [12]. Nonetheless, current guidelines
for the treatment of PHN, including guidelines issued in
2010 and 2011, emphasize pharmacological manage-
ment. While some guidelines acknowledge the impor-
tance of prevention, none have highlighted preventative
steps or recognized the role of the herpes zoster vaccine
in preventing PHN [13–16]. The treatment of AHZ often
includes antiviral agents such as aciclovir or famciclovir;
however, these agents do not reduce the likelihood of
subsequently developing PHN [17].
3 Diagnosis of Postherpetic Neuralgia (PHN)
3.1 Patient History
Although AHZ is typically easily recognizable, PHN can
be difficult to diagnose because a patient with pain long
after the AHZ rash has cleared up may not remember the
rash or associate the current pain with it. In the diagnosis of
PHN, routine questioning should attempt to identify the
nature of the patient’s pain (Table 1). In PHN, the pain is
typically discretely localized and unilateral (i.e. dermato-
mal), intermittent, chronic and sufficiently intense to
interfere with sleep and other normal daily activities.
Additionally, the pain may have an itching, burning, sharp,
stabbing or throbbing quality. Aggravating factors include
light touch, such as the touch of clothing or standing in a
shower. Relieving factors may include barriers to touch
[1, 2].
The patient history may reveal conditions that may help
differentially diagnosis PHN, including a recent history or
the presence of herpes simplex virus, impetigo, candidiasis,
contact dermatitis, insect bites, autoimmune blistering
disease, dermatitis herpetiformis and drug-related eruptions
[2].
With AHZ, however, nerve pain may emerge in the
absence of any skin eruption, as in a condition called zoster
sine herpete or in the presence of intercostal neuralgia [18,
19]. Nevertheless, pain following a documented episode of
AHZ usually provides clear evidence for a diagnosis of
PHN. This evidence may be particularly compelling when
Table 1 Diagnostic steps in postherpetic neuralgia
Step Diagnosis notes
1. Patient history Routine questioning should identify the source of the patient’s pain
Pain is typically discrete and unilateral and displays an itching, burning, sharp, stabbing or throbbing quality
Pain is intermittent and chronic in nature
Pain is sufficiently intense to interfere with normal daily activities
Pain following a documented episode of AHZ provides compelling evidence for a diagnosis of PHN
2. Physical
examination
Areas of previous AHZ infection may manifest evidence of cutaneous scarring
Affected area may display either hypersensitivity or hyposensitivity to pain
Allodynia may occur in the pain-producing area
Autonomic changes may also occur in the affected area, including increased sweating
3. Laboratory
investigations
PHN diagnosis does not rely on laboratory evaluations
Viral culture or immunofluorescent staining may be used to distinguish herpes simplex from herpes zoster
Presence of antibodies to herpes zoster may help support diagnosis of subclinical herpes zoster infection, especially in
the case of zoster sine herpete
Other laboratory tests may be useful in confirming a herpes zoster infection, including immunoperoxidase staining,
histopathology and the Tzanck smear
AHZ acute herpes zoster, PHN postherpetic neuralgia
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additional PHN risk factors are present [2, 19], including
advanced age, severe prodromal pain, severe rash, AHZ
localized in the trigeminal dermatomes and brachial
plexus, and symptoms of allodynia.
3.2 Physical Examination
During the physical examination, areas of previous AHZ may
show evidence of cutaneous scarring [19]. In approximately
50 % of patients with PHN, dynamic mechanical allodynia
occurs in the pain-producing area in response to normally
nonpainful stimuli, such as light touch by a brush. Thermal
hyperalgesia is present in approximately one-third of patients.
However, in some cases, decreased sensation or numbness
may be experienced by the patient [20].
4 Management of PHN
4.1 First-Line Therapies
Tricyclic antidepressants, gabapentin and pregabalin, and
the topical lidocaine 5 % patch are each categorized as
first-line treatments for PHN in guidelines issued by the
American Academy of Neurology (2004) [14], the Inter-
national Association for the Study of Pain (2007) [21], and
the European Federation of Neurological Societies (2010)
[13] (Table 2). However, topical lidocaine (as a gel, cream
or patch) is considered a second-line or third-line therapy
in British [16] and Canadian guidelines [22]. Opioids,
tramadol, capsaicin cream and the capsaicin 8 % patch are
usually considered either second- or third-line treatments
because of safety and/or efficacy disadvantages compared
with first-line therapies.
4.1.1 Tricyclic Antidepressants
The tricyclic antidepressants amitriptyline, nortriptyline,
imipramine and desipramine act by increasing serotonin
and norepinephrine levels and blocking voltage-dependent
sodium channels and a-adrenergic receptors, actions
important in modulating descending pain pathways [23].
The efficacy of tricyclic antidepressants in the treatment of
PHN pain is well established [3]. In a 2005 systematic
review, the combined number needed to treat (NNT) with
amitriptyline, nortriptyline or desipramine to obtain a sin-
gle patient with a 50 % reduction in PHN pain (compared
with placebo) was 2.5 [24]. Despite their efficacy, tricyclic
antidepressants for PHN may not be the most appropriate
option for all patients. These agents display a relatively
slow onset of action and have the potential for troublesome
systemic adverse events, such as dry mouth, constipation,
urinary retention and sedation. They have also been linked
to cardiotoxic events, including myocardial infarction and
cardiac dysrhythmias [2, 3, 25]. Thus, in some patients––
especially those most susceptible to tricyclic antidepressant
adverse events and cardiotoxicities, such as the elderly––
alternative PHN treatments may be considered.
4.1.2 Gabapentin and Pregabalin
The anticonvulsants gabapentin and pregabalin bind to a2-d
proteins, where they act as voltage-gated calcium channel
blockers, inhibiting central pain pathways [23]. Although both of
these agents act at the same receptor site, pregabalin may offer a
more predictable and linear pharmacokinetic profile than gaba-
pentin [2]. In the Cochrane Database of Systematic Reviews, the
NNT to obtain a patient with a 50 % reduction in pain was 7.5 for
gabapentin [26] and 5.0–11 for pregabalin 300–600 mg [27]. As
with tricyclic antidepressant treatment, adverse events with these
agents may limit their use in some patients. In clinical studies, the
most common adverse events with gabapentin and pregabalin
included somnolence (up to 25 %) and dizziness (up to 46 %)
[26, 27]. In addition, both agents may cause dry mouth, weight
gain or peripheral oedema [28].
4.1.3 Lidocaine 5 % Patch
Lidocaine blocks voltage-gated sodium channels, decreasing
ectopic impulses generated by damaged primary afferent pain
receptors, thus attenuating PHN pain perception [23]. The
lidocaine 5 % patch also incorporates a barrier effect similar
to a cloth bandage. This therapy has a rapid onset of action
(B4 h). In clinical trials (4–12 weeks), C50 % reductions in
pain have been reported in approximately one-quarter to one-
third of patients [29–31]. Moreover, results from two 4-week
open-label clinical studies indicated that the lidocaine 5 %
patch was more effective than pregabalin for alleviating PHN
pain [29, 32]. Efficacy and safety for B24 months has been
demonstrated [33]. The NNT (calculated from small studies)
for a C50 % reduction in neuropathic pain ranged from 2.0 to
4.4 [22, 24, 34].
Table 2 Treatment options for postherpetic neuralgia
Treatment type Drug/drug class
First-line Tricyclic antidepressants
Anticonvulsants such as gabapentin and pregabalin






Lidocaine 5 % topical patch in combination with
systemic agent such as pregabalin
Systemic agents combinations such as gabapentin/
nortriptyline or morphine/gabapentin
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The lidocaine 5 % patch is generally well tolerated. The
application of 3–4 patches daily results in systemic lido-
caine concentrations of\200 ng/mL [35, 36], a level much
lower than that required to trigger systemic (1,500 ng/mL)
adverse events or cardiovascular toxicity (5,000 ng/mL)
[37]. In a 12-month open-label trial, [33] the most frequent
treatment-related adverse events were mild-to-moderate
application-site reactions, such as transient pruritus, ery-
thema and dermatitis.
4.2 Second-Line and Third-Line Therapies
4.2.1 Opioid Analgesics
The role of opioid analgesics in the management of PHN
remains controversial [2]. Strong opioids, such as oxycodone,
morphine and methadone, provide effective analgesia in
patients with PHN that is at least comparable to tricyclic
antidepressants [38]. In a 2005 systematic review, the NNT for
a 50 % reduction in PHN pain with the strong opioids oxy-
codone and morphine was 2.5 and 2.7, respectively [24].
However, the long-term use of these analgesics presents a risk
for potentially treatment-limiting adverse events, including
nausea, sedation and constipation [38]. Tramadol, a centrally
acting weak opioid and monoaminergic inhibitor, has proven
less effective than strong opioids in PHN pain, but may be
better tolerated than strong opioids [34]. The NNT for a 50 %
reduction in PHN pain with tramadol was 4.8 [24].
4.2.2 Capsaicin
Capsaicin, a vanilloid type I receptor agonist, provides
analgesia by activating and, in turn, desensitizing nerve
fibres in the skin over time [39]. Capsaicin cream and the
capsaicin 8 % patch have each demonstrated efficacy in
patients with PHN [40–42]. Although capsaicin cream
induces significant analgesia within 2 weeks of treatment
initiation, maximal analgesic effect requires at least
4 weeks of treatment [42]. In a systematic review, the NNT
(calculated from small studies) for a 50 % reduction in
PHN pain with capsaicin cream was 2.7–3.4 [24]. The
capsaicin 8 % patch has been shown to be more effective
than conventional capsaicin cream formulations [43],
though the NNT for a 50 % reduction in PHN pain cal-
culated using data from a large clinical trial was 10.4 [44].
With the use of capsaicin cream, patients should expect
discomfort before the onset of meaningful pain relief.
Capsaicin cream requires repeated applications before the
onset of meaningful analgesia, and many patients are
unable to tolerate the associated burning sensation [41, 42].
In fact, application-site reactions, such as burning, stinging
and erythema, occurred in more than 60 % of patients early
in capsaicin treatment and were a major reason for
treatment discontinuation [42]. The capsaicin 8 % patch
must be administered in a clinic or hospital under medical
supervision as a single treatment every 3 months in com-
bination with a local anaesthetic, a potentially major lim-
itation to routine use. Even with a local anaesthetic,
patients may experience post-procedural pain requiring
systemic analgesics such as opioids [45].
4.3 Rational Polypharmacy
In the treatment of PHN and other neuropathic pain conditions,
single-drug therapy may not provide sufficient analgesia even
when administered at maximum tolerable doses [46]. A single
agent alone may not be capable of effectively modifying the
complex pain mechanisms that underlie PHN. Consequently,
the use of multiple agents with different mechanisms of action
may be required to provide enhanced pain relief. Toward this
end, guidelines for the management of neuropathic pain
advocate the use of combination regimens, especially the
topical lidocaine 5 % patch and an oral agent, when a single
agent fails to offer acceptable PHN pain relief [21].
4.3.1 Lidocaine 5 % Patch Combination Therapy
In a randomized, clinical trial, patients not responding
sufficiently to the lidocaine 5 % patch or pregabalin
monotherapy after 4 weeks received combination therapy
for 8 additional weeks [32]. During the monotherapy
phase, 14 subjects (29 %) adequately responded to pre-
gabalin and 25 (50 %) to the lidocaine 5 % patch. During
combination therapy, 18 patients added pregabalin to the
lidocaine 5 % patch, and 17 added the lidocaine 5 % patch
to pregabalin, at the same doses used in monotherapy.
Combination therapy yielded clinically relevant reductions
in PHN pain. During the monotherapy phase, the lidocaine
5 % patch was significantly better tolerated than pregaba-
lin, with the incidence of drug-related adverse events
substantially lower in patients with the lidocaine 5 % patch
(10 %) than with pregabalin (52.1 %). Combination treat-
ment was generally well tolerated. As with monotherapy,
most adverse events were attributed to pregabalin treat-
ment. A pregabalin dose-sparing effect was observed when
the lidocaine 5 % patch was added to pregabalin therapy.
In a down-titration subtrial, pregabalin could be withdrawn
from this combination therapy without pain relapse,
implying that the improvement seen in pregabalin-treated
patients with combination therapy may have been primarily
the result of lidocaine treatment [32].
4.3.2 Other Combination Therapies
In the management of PHN pain, clinical studies also
suggest that gabapentin combined with nortriptyline or
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morphine combined with gabapentin yields greater reduc-
tions in PHN pain than either modality alone; however, the
rate of drug-specific adverse events remained high [3].
5 Conclusions
PHN remains a potentially debilitating and undertreated
form of neuropathic pain. Over the past decade, clinical
findings and treatment guidelines have underscored the
importance of increased clinician awareness of the signs
and symptoms of this chronically painful disorder and
the importance of deploying evidence-based treatment
modalities to improve outcome.
A medical consensus has emerged on what is considered
best practice in the management of PHN. Because of the
virtually universal presence of varicella zoster infection, a
direct antecedent of AHZ, individuals at least 50 years of
age should receive the AHZ vaccine to minimize their risk
of both AHZ and PHN.
In patients with PHN, first-line systemic therapies, such
as tricyclic antidepressants (amitriptyline, nortriptyline and
desipramine) and gabapentinoids (gabapentin and pregab-
alin) have demonstrated efficacy, but may not be the most
appropriate therapy for all patients because of their rela-
tively slow onset of action and potential for treatment-
limiting systemic adverse events. The lidocaine 5 % patch,
listed as a first-line therapy in some guidelines, has a rapid
onset of pain relief and a minimal risk for systemic adverse
events, although application-site reactions occur in a
minority of patients. Topical capsaicin cream or the cap-
saicin patch is considered second- or third-line therapy not
only because capsaicin appears to be less effective than
first-line therapies but also because it can trigger treatment-
limiting application-site reactions. Additionally, clinical
studies reveal that, in the management of PHN, combina-
tion therapy with two agents that display different mech-
anisms of action may bolster efficacy in patients who do
not adequately respond to either treatment alone. This
strategy usually incorporates a systemic and topical ther-
apy, chiefly the lidocaine 5 % patch. Use of a topical
analgesic in this way may provide additional analgesia
without having a significant negative impact on the
occurrence of systemic adverse events. In some patients, it
may be clinically plausible to initiate the treatment of PHN
with a topical agent, such as the lidocaine 5 % patch,
before resorting to a systemic therapy, and to switch to or
add on a systemic therapy when necessary to achieve sat-
isfactory pain control.
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